Activation of Poly(ADP-Ribose) Polymerase by Myocardial Ischemia and Coronary Reperfusion in Human Circulating Leukocytes

Reactive free radical and oxidant production leads to DNA damage during myocardial Ischemia/reperfusion. Consequent overactivation of poly(ADP-ribose) polymerase (PARP) promotes cellular energy deficit and necrosis. We hypothesized that PARP is activated in circulating leukocytes in patients with myocardial infarction and reperfusion during primary percutaneous coronary intervention (PCI). In 15 patients with ST segment elevation acute myocardial infarction, before and after primary PCI and 24 and 96 h later, we determined serum hydrogen peroxide concentrations, plasma levels of the oxidative DNA adduct 8-hydroxy-2′-deoxyguanosine (8OHdG), tyrosine nitration, PARP activation, and translocation of apoptosis-inducing factor (AIF) in circulating leukocytes. Plasma 8OHdG levels and leukocyte tyrosine nitration were rapidly increased by PCI. Similarly, poly(ADP-ribose) content of the leukocytes increased in cells isolated just after PCI, indicating immediate PARP activation triggered by reperfusion of the myocardium. In contrast, serum hydrogen peroxide concentrations and the translocation of AIF gradually increased over time and were most pronounced at 96 h. Reperfusion-related oxidative/nitrosative stress triggers DNA damage, which leads to PARP activation in circulating leukocytes. Translocation of AIF and lipid peroxidation occurs at a later stage. These results represent the first direct demonstration of PARP activation in human myocardial infarction. Future work is required to test whether pharmacological inhibition of PARP may offer myocardial protection during primary PCI.

[1]  C. Szabó Cardioprotective effects of poly(ADP-ribose) polymerase inhibition. , 2005, Pharmacological research.

[2]  G. Graziani,et al.  Clinical perspectives of PARP inhibitors. , 2005, Pharmacological research.

[3]  Csaba Szabó,et al.  Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors , 2005, Nature Reviews Drug Discovery.

[4]  M. Fuertes,et al.  Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications. , 2005, Progress in biophysics and molecular biology.

[5]  C. Vrints,et al.  Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process. , 2005, International journal of cardiology.

[6]  C. Szabó,et al.  Mitochondrial-to-nuclear translocation of apoptosis-inducing factor in cardiac myocytes during oxidant stress: potential role of poly(ADP-ribose) polymerase-1. , 2004, Cardiovascular research.

[7]  D. Giugliano,et al.  Intermittent high glucose enhances ICAM‐1, VCAM‐1, E‐selectin and interleukin‐6 expression in human umbilical endothelial cells in culture: the role of poly(ADP‐ribose) polymerase , 2004, Journal of thrombosis and haemostasis : JTH.

[8]  K. Murthy,et al.  Activation of Poly(ADP-Ribose) Polymerase in Circulating Leukocytes During Myocardial Infarction , 2004, Shock.

[9]  J. Yélamos,et al.  Transcription regulation of TNF-alpha-early response genes by poly(ADP-ribose) polymerase-1 in murine heart endothelial cells. , 2004, Nucleic acids research.

[10]  F. Sellke,et al.  Poly(ADP-ribose) polymerase inhibition improves postischemic myocardial function after cardioplegia-cardiopulmonary bypass. , 2003, Journal of the American College of Surgeons.

[11]  É. Szabó,et al.  Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention. , 2003, Toxicology letters.

[12]  C. Schäfer,et al.  Cellular mechanisms of ischemia-reperfusion injury. , 2003, The Annals of thoracic surgery.

[13]  C. Szabó,et al.  The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors , 2002, Pharmacological Reviews.

[14]  M. Simoons,et al.  Minor Myocardial Damage and Prognosis: Are Spontaneous and Percutaneous Coronary Intervention–Related Events Different? , 2002, Circulation.

[15]  É. Szabó,et al.  Suppression of poly (ADP‐ribose) polymerase activation by 3‐aminobenzamide in a rat model of myocardial infarction: long‐term morphological and functional consequences , 2001, British journal of pharmacology.

[16]  Z. Berente,et al.  Effect of poly(ADP-ribose) polymerase inhibitors on the ischemia-reperfusion-induced oxidative cell damage and mitochondrial metabolism in Langendorff heart perfusion system. , 2001, Molecular pharmacology.

[17]  R. Califf,et al.  The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. , 1999, Journal of the American College of Cardiology.

[18]  R. Ferrari,et al.  Metabolic derangement in ischemic heart disease and its therapeutic control. , 1998, The American journal of cardiology.

[19]  B. Zingarelli,et al.  Genetic disruption of poly (ADP-ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury. , 1998, Circulation research.

[20]  R. Califf,et al.  Myonecrosis after revascularization procedures. , 1998, Journal of the American College of Cardiology.

[21]  S. Cuzzocrea,et al.  Protection against myocardial ischemia and reperfusion injury by 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase. , 1997, Cardiovascular research.

[22]  B. Zingarelli,et al.  Protection by inhibition of poly (ADP-ribose) synthetase against oxidant injury in cardiac myoblasts In vitro. , 1997, Journal of molecular and cellular cardiology.

[23]  S. Maxwell,et al.  Reperfusion injury: a review of the pathophysiology, clinical manifestations and therapeutic options. , 1997, International journal of cardiology.

[24]  C. Thiemermann,et al.  Inhibition of the activity of poly(ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Brown,et al.  A Randomised Controlled Trial of Vitamin E in Patients with Coronary Disease: The Cambridge Heart Antioxidant Study (CHAOS) , 1996 .

[26]  F. Kelly,et al.  Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) , 1996, The Lancet.

[27]  D. Carrié,et al.  Myocardial protection with calcium-channel blockers during ischaemia and reperfusion by PTCA. , 1995, European heart journal.

[28]  J. Kirkland,et al.  Lipid peroxidation, protein thiol oxidation and DNA damage in hydrogen peroxide-induced injury to endothelial cells: role of activation of poly(ADP-ribose)polymerase. , 1991, Biochimica et biophysica acta.

[29]  J. Zweier Measurement of superoxide-derived free radicals in the reperfused heart. Evidence for a free radical mechanism of reperfusion injury. , 1988, The Journal of biological chemistry.

[30]  E. Braunwald,et al.  Myocardial reperfusion: a double-edged sword? , 1985, The Journal of clinical investigation.

[31]  M S Golden,et al.  Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. , 1980, The New England journal of medicine.

[32]  H. Eltzschig,et al.  Vascular ischaemia and reperfusion injury. , 2004, British medical bulletin.

[33]  Z. Yang,et al.  Effect of genetic disruption of poly (ADP-ribose) synthetase on delayed production of inflammatory mediators and delayed necrosis during myocardial ischemia-reperfusion injury. , 2000, Shock.